Healthcare
Corcept Therapeutics Inc(CORT)
Live Price
Offline$79.91
-2.25% today
1Y Change
+10.23%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $5.51B
- Revenue Growth
- +12.8%
- EPS Growth
- -29.6%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Corcept Therapeutics Inc (CORT) is a Healthcare stock with a market cap of $5.51B and listed on NASDAQ. The stock last traded around $79.91 and up 10.2% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +12.8%, EPS growth of -29.6%, a dividend yield of 0.0%. What stands out right now is revenue +12.8%, EPS -29.6%, free cash flow -27.6% with operating margin -1.1% and ROIC -1.2%. Valuation already assumes a fairly strong business story at P/E 111.9 and price/sales 7.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CORT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.8% vs +7.6% peer median
Operating Margin
Below sector median
-1.1% vs +19.4% peer median
P/E
Above sector median
111.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +12.8% and EPS is at -29.6%, with operating margin around -1.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -0.5% | -0.8% | +38.0% |
2026 Feb 24, 2026 | -39.4% | -0.7% | -3.3% | -7.3% |
2025 Nov 4, 2025 | -11.1% | +7.8% | +11.1% | +17.7% |
Benchmark Edge
CORT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CORT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CORT Max Drawdown
-64.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CORT and SPY.
Company Overview
Corcept Therapeutics Inc
NASDAQ
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs that modulate cortisol effects to treat severe endocrinologic, metabolic, oncologic, and neurologic disorders. Its flagship product, Korlym, is a cortisol receptor blocker used to control hyperglycemia in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for it. The company advances a pipeline of selective cortisol modulators, including relacorilant, targeting conditions such as hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS), and liver disease. Operating in the health technology sector, specifically pharmaceuticals, Corcept Therapeutics Incorporated addresses unmet needs in rare and serious disorders through innovative therapies that mitigate excess cortisol's adverse impacts. Founded in 1998 and headquartered in Redwood City, California, it plays a key role in advancing treatments for cortisol-related pathologies.
- Leadership
- Dr. Joseph K. Belanoff M.D.
- Employees
- 500
- Street Address
- 101 Redwood Shores Parkway
- Mailing
- Redwood City, CA, 94065
- Region
- Redwood City, CA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 111.9
- EV/EBITDA
- โ
- Price/Sales
- 7.2
- Price/Book
- 8.4
Growth
- Revenue
- +12.8%
- EPS
- -29.6%
- Free Cash Flow
- -27.6%
Profitability
- Gross Margin
- 98.3%
- Operating Margin
- -1.1%
- Net Margin
- 6.2%
- ROE
- 7.5%
- ROIC
- -1.2%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 2.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.